Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2019-07-24
DOI
10.1093/jac/dkz353
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical significance of elevated liver transaminases in HIV-infected patients
- (2019) Jia Cai et al. AIDS
- Sexualized drug use (‘chemsex’) and high-risk sexual behaviours in HIV-positive men who have sex with men
- (2018) EL Pufall et al. HIV MEDICINE
- First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison
- (2018) L Taramasso et al. HIV MEDICINE
- EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
- (2018) Mark Thursz et al. JOURNAL OF HEPATOLOGY
- Hepatitis A outbreak disproportionately affecting men who have sex with men (MSM) in the European Union and European Economic Area, June 2016 to May 2017
- (2018) Patricia Ndumbi et al. Eurosurveillance
- Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population?
- (2018) Georgia Vourli et al. AIDS
- Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature
- (2017) Bo Wang et al. INTERNATIONAL JOURNAL OF STD & AIDS
- Tolerability of integrase inhibitors in a real-life setting
- (2017) Judit Peñafiel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project
- (2017) Nicola Squillace et al. PLoS One
- Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
- (2017) Pedro Cahn et al. Lancet HIV
- Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status
- (2017) Charitha Gowda et al. Open Forum Infectious Diseases
- Abacavir/Dolutegravir/Lamivudine (Triumeq)–Induced Liver Toxicity in a Human Immunodeficiency Virus–Infected Patient
- (2017) Erin S. Christensen et al. Open Forum Infectious Diseases
- Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice
- (2016) Mark G.J. de Boer et al. AIDS
- Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
- (2016) C Hoffmann et al. HIV MEDICINE
- Discontinuation of Initial Antiretroviral Therapy in Clinical Practice
- (2016) Antonio Di Biagio et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis
- (2016) Lucy Platt et al. LANCET INFECTIOUS DISEASES
- Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial
- (2016) Nathalie de Castro et al. AIDS Research and Therapy
- Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals
- (2015) L. Taramasso et al. BIOMEDICINE & PHARMACOTHERAPY
- Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients
- (2015) Giuseppe Lapadula et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1
- (2014) Jeffrey L. Lennox et al. ANNALS OF INTERNAL MEDICINE
- Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C
- (2014) Christopher B Hurt et al. ANTIVIRAL THERAPY
- Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor–Naive Patients
- (2014) L. Curtis et al. HIV CLINICAL TRIALS
- Liver Enzyme Elevation During Darunavir-Based Antiretroviral Treatment in HIV-1–Infected Patients With or Without Hepatitis C Coinfection: Data from the ICONA Foundation Cohort
- (2014) Antonio Di Biagio et al. HIV CLINICAL TRIALS
- Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
- (2014) Bonaventura Clotet et al. LANCET
- Association Between ALT Level and the Rate of Cardio/Cerebrovascular Events in HIV-Positive Individuals
- (2013) Caroline A. Sabin et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients
- (2013) Jürgen K. Rockstroh et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
- (2013) Francois Raffi et al. LANCET
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV–hepatitis C virus coinfected patients
- (2012) Eugenia Vispo et al. AIDS
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
- (2012) Paul E Sax et al. LANCET
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
- (2012) Edwin DeJesus et al. LANCET
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
- (2011) Jan van Lunzen et al. LANCET INFECTIOUS DISEASES
- Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression
- (2010) David M Iser et al. AIDS
- Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV‐Infected Persons without Hepatitis B or C Virus Co‐Infection
- (2010) Helen Kovari et al. CLINICAL INFECTIOUS DISEASES
- Prevalence and Factors Associated With Liver Test Abnormalities Among Human Immunodeficiency Virus–Infected Persons
- (2009) Nancy Crum–Cianflone et al. Clinical Gastroenterology and Hepatology
- Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C
- (2009) E. Vispo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started